MXPA05011965A - Analogos inmunogenicos de tnf-alfa humano con citotoxicidad reducida y metodos para su preparacion. - Google Patents

Analogos inmunogenicos de tnf-alfa humano con citotoxicidad reducida y metodos para su preparacion.

Info

Publication number
MXPA05011965A
MXPA05011965A MXPA05011965A MXPA05011965A MXPA05011965A MX PA05011965 A MXPA05011965 A MX PA05011965A MX PA05011965 A MXPA05011965 A MX PA05011965A MX PA05011965 A MXPA05011965 A MX PA05011965A MX PA05011965 A MXPA05011965 A MX PA05011965A
Authority
MX
Mexico
Prior art keywords
analogue
tnfalpha
provides
detoxified
tnf
Prior art date
Application number
MXPA05011965A
Other languages
English (en)
Inventor
Bjoern Voldborg
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of MXPA05011965A publication Critical patent/MXPA05011965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona un analogo inmunogenico de una proteina TNF( humana, en donde el analogo comprende un polipeptido de TNF( monomerico, inmunogenizado o dimero o trimero de TNF(, y en donde el analogo comprende ademas una mutacion de reduccion o de abolicion de la toxicidad, seleccionada del grupo que consiste de Y87S, D143N o A145R, la numeracion de los aminoacidos se establece desde la valina N-terminal en el TNF( humano. La invencion tambien proporciona un fragmento de acido nucleico que codifica para el analogo, asi como para los vectores y las celulas transformadas utiles en la preparacion del analogo. Tambien se describen los metodos de subregulacion de TNF( en un sujeto en necesidad de la misma.
MXPA05011965A 2003-05-09 2004-05-06 Analogos inmunogenicos de tnf-alfa humano con citotoxicidad reducida y metodos para su preparacion. MXPA05011965A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46949103P 2003-05-09 2003-05-09
DKPA200300701 2003-05-09
PCT/DK2004/000329 WO2004099244A2 (en) 2003-05-09 2004-05-06 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation

Publications (1)

Publication Number Publication Date
MXPA05011965A true MXPA05011965A (es) 2006-02-02

Family

ID=33436006

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011965A MXPA05011965A (es) 2003-05-09 2004-05-06 Analogos inmunogenicos de tnf-alfa humano con citotoxicidad reducida y metodos para su preparacion.

Country Status (11)

Country Link
US (1) US20060222624A1 (es)
EP (1) EP1625157A2 (es)
JP (1) JP2007523605A (es)
KR (1) KR20060015595A (es)
AU (1) AU2004235875A1 (es)
CA (1) CA2524623A1 (es)
EA (1) EA008254B1 (es)
MX (1) MXPA05011965A (es)
NO (1) NO20055724L (es)
NZ (1) NZ543976A (es)
WO (1) WO2004099244A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054937A (en) 1975-01-28 1979-05-22 Gursaran P. Talwar Antipregnancy vaccine
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
WO1986007383A1 (en) 1985-06-04 1986-12-18 Biotechnology Research Partners, Ltd. Autoantigen vaccines
JPH02177896A (ja) * 1988-12-28 1990-07-10 Teijin Ltd 新規生理活性ポリペプチド
US20030185845A1 (en) * 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins
IL161708A0 (en) * 2001-11-16 2004-09-27 Pharmexa As Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts

Also Published As

Publication number Publication date
JP2007523605A (ja) 2007-08-23
CA2524623A1 (en) 2004-11-18
WO2004099244A3 (en) 2004-12-29
EA200501773A1 (ru) 2006-06-30
US20060222624A1 (en) 2006-10-05
KR20060015595A (ko) 2006-02-17
EA008254B1 (ru) 2007-04-27
AU2004235875A1 (en) 2004-11-18
NZ543976A (en) 2008-04-30
WO2004099244A2 (en) 2004-11-18
NO20055724L (no) 2005-11-30
EP1625157A2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
WO2001031019A3 (en) Neisserial antigenic peptides
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
WO2000075350A3 (en) Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use
HUP0101734A2 (hu) Béta-amiloid prekurzor protein és ubiquitin-B kereteltolódásos mutánsok és alkalmazásuk
MX361694B (es) Fragmentos de peptidos para inducir sintesis de proteinas de matriz extra-celular.
IL184112A0 (en) A method for producing polypeptides or proteins in a disulfide-bridged two-chain form
WO1994018332A3 (en) Anthrax toxin fusion proteins and uses thereof
NZ591415A (en) Haemophilus influenzae type B
EP0963435A4 (en) PROTEIN PRODUCTION PROCESSES
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
WO2006131749A3 (en) Scaffold
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
SG146662A1 (en) Method
AU2001259217A1 (en) Human pellino polypeptides
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
MXPA05011965A (es) Analogos inmunogenicos de tnf-alfa humano con citotoxicidad reducida y metodos para su preparacion.
AU5776799A (en) Modified hcv peptide vaccines
WO2002004630A3 (en) Methods for recombinatorial nucleic acid synthesis
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
ATE273391T1 (de) Neurotrophischer faktor nnt-1
WO2004092195A3 (en) Dendritic cell binding proteins and uses thereof
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.